Cue Biopharma Net Worth
Cue Biopharma Net Worth Breakdown | CUE |
Cue Biopharma Net Worth Analysis
Cue Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Cue Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Cue Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Cue Biopharma's net worth analysis. One common approach is to calculate Cue Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Cue Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Cue Biopharma's net worth. This approach calculates the present value of Cue Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Cue Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Cue Biopharma's net worth. This involves comparing Cue Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Cue Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Cue Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cue Biopharma's net worth research are outlined below:
| Cue Biopharma is way too risky over 90 days horizon | |
| Cue Biopharma has some characteristics of a very speculative penny stock | |
| Cue Biopharma appears to be risky and price may revert if volatility continues | |
| Cue Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 5.49 M. Reported Net Loss for the year was (50.73 M) with profit before taxes, overhead, and interest of 1.25 M. | |
| Cue Biopharma has about 66.13 M in cash with (39.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cue Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Cue BiopharmaReports Third Quarter 2024 Financial Results and Recent Business Highlights |
Cue Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cue Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cue Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Cue Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cue Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cue Biopharma backward and forwards among themselves. Cue Biopharma's institutional investor refers to the entity that pools money to purchase Cue Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisory Research Inc | 2024-06-30 | 257.2 K | Bank Of America Corp | 2024-06-30 | 242.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 242 K | Stifel Financial Corp | 2024-06-30 | 194 K | State Street Corp | 2024-06-30 | 177.1 K | Y-intercept (hong Kong) Ltd | 2024-06-30 | 153.6 K | Northern Trust Corp | 2024-09-30 | 138.3 K | Susquehanna International Group, Llp | 2024-06-30 | 119.7 K | Jane Street Group Llc | 2024-06-30 | 98.6 K | Bleichroeder Lp | 2024-09-30 | 5 M | Slate Path Capital Lp | 2024-09-30 | 2.4 M |
Follow Cue Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 64.62 M.Market Cap |
|
Project Cue Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.87) | |
| Return On Capital Employed | (1.17) | (1.23) | |
| Return On Assets | (0.82) | (0.87) | |
| Return On Equity | (1.37) | (1.44) |
When accessing Cue Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Cue Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cue Biopharma's profitability and make more informed investment decisions.
Please note, the presentation of Cue Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cue Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cue Biopharma's management manipulating its earnings.
Evaluate Cue Biopharma's management efficiency
Cue Biopharma has Return on Asset of (0.5211) % which means that on every $100 spent on assets, it lost $0.5211. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.3887) %, meaning that it generated no profit with money invested by stockholders. Cue Biopharma's management efficiency ratios could be used to measure how well Cue Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.87. In addition to that, Return On Capital Employed is expected to decline to -1.23. At present, Cue Biopharma's Total Current Assets are projected to increase significantly based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.81 | 1.40 | |
| Tangible Book Value Per Share | 0.81 | 1.40 | |
| Enterprise Value Over EBITDA | (1.89) | (1.98) | |
| Price Book Value Ratio | 3.26 | 3.09 | |
| Enterprise Value Multiple | (1.89) | (1.98) | |
| Price Fair Value | 3.26 | 3.09 | |
| Enterprise Value | 87 M | 82.6 M |
Cue Biopharma benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Enterprise Value Revenue 4.3757 | Revenue 8.3 M | Quarterly Revenue Growth 0.923 | Revenue Per Share 0.172 | Return On Equity (1.39) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cue Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cue Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cue Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cue Biopharma time-series forecasting models is one of many Cue Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cue Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Cue Biopharma Earnings per Share Projection vs Actual
Cue Biopharma Corporate Management
| JD MSc | CEO Director | Profile | |
| Kenneth MD | Acting Officer | Profile | |
| Steven Almo | CoFounder Board | Profile | |
| Matteo MD | Chief Officer | Profile | |
| Dr III | CoFounder | Profile | |
| Lucinda Warren | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.